Geron Corporation (GERN) : Analyst Rating Update

Geron Corporation (GERN) : 4 analysts are covering Geron Corporation (GERN) and their average rating on the stock is 1.5, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Geron Corporation (GERN) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $10 and the lowest price target forecast is $6. The average forecast of all the analysts is $7.5 and the expected standard deviation is $2.18.

Geron Corporation (NASDAQ:GERN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.64 and $2.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.73. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.68, notching a gain of 0.37% for the day. The total traded volume was 1,420,829 . The stock had closed at $2.67 on the previous day.

The company shares have dropped -33.75% from its 1 Year high price. On Dec 2, 2015, the shares registered one year high at $5.30 and the one year low was seen on Feb 26, 2016. The 50-Day Moving Average price is $2.79 and the 200 Day Moving Average price is recorded at $3.06.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.